Expertise in
11
conditions

Dr. Joseph Tauber

Ophthalmology
4400 Broadway Blvd Ste 202, 
Kansas City, MO 
On Staff At
Expertise in
11
conditions
4400 Broadway Blvd Ste 202, 
Kansas City, MO 

Overview

Joseph Tauber is an Ophthalmologist in Kansas City, Missouri. Dr. Tauber is highly rated in 11 conditions, according to our data. His top areas of expertise are Dry Eye Syndrome, Meibomianitis, Conjunctivitis (Pink Eye), Episcleritis, and Corneal Transplant.

His clinical research consists of co-authoring 30 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Ophthalmology

Licenses

Ophthalmology in KS

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Insight Eyecare Specialties
4400 Broadway Blvd Ste 202, Kansas City, MO 64111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Betamethasone Sodium Phosphate
Study Phase: Phase 2
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: Combination of Mycophenolic Acid and Betamethasone Sodium Phosphate, Mycophenolic Acid, Restasis Ophthalmic Emulsion, Xiidra Ophthalmic Solution
Study Phase: Phase 2
A 4 Weeks, Phase II, Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 12 Weeks of Follow-up to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution vs Vehicle in Moderate to Severe Dry Eye.
A 4 Weeks, Phase II, Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 12 Weeks of Follow-up to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution vs Vehicle in Moderate to Severe Dry Eye.
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation
A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug, Device
Study Phase: Phase 1/Phase 2
A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use
A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation
A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation
Enrollment Status: Completed
Publish Date: January 29, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
Enrollment Status: Completed
Publish Date: August 29, 2019
Intervention Type: Drug
Study Phase: Phase 1
Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days
Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days
Enrollment Status: Terminated
Publish Date: October 11, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

30 Total Publications

TFOS DEWS III.
TFOS DEWS III.
Journal: American journal of ophthalmology
Published: November 23, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Abraham Poulose
Ophthalmology
Expertise in
18
conditions
Dr. Abraham Poulose
Ophthalmology

Office

4320 Wornall Rd Ste 220, 
Kansas City, MO 
 (0.1 miles away)
816-234-3046
Languages Spoken:
English
See accepted insurances

Abraham Poulose is an Ophthalmologist in Kansas City, Missouri. Dr. Poulose is highly rated in 18 conditions, according to our data. His top areas of expertise are Diabetic Retinopathy, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, and Retinal Artery Occlusion.

Jason A. Sokol
Expertise in
15
conditions
Dr. Jason A. Sokol
Ophthalmology
Expertise in
15
conditions
Dr. Jason A. Sokol
Ophthalmology

Eye Center

7400 State Line Road, Suite 100, 
Prairie Village, KS 
 (3.8 miles away)
913-588-1227
Experience:
22+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Jason Sokol is an Ophthalmologist in Prairie Village, Kansas. Dr. Sokol has been practicing medicine for over 22 years is highly rated in 15 conditions, according to our data. His top areas of expertise are Graves Disease, Anophthalmia Plus Syndrome, Blocked Tear Duct, Melanoma of the Eye, and Tissue Biopsy. Dr. Sokol is currently accepting new patients.

Expertise in
20
conditions
Dr. Komal Desai
Ophthalmology
Expertise in
20
conditions
Dr. Komal Desai
Ophthalmology

Office

4320 Wornall Rd Ste 220, 
Kansas City, MO 
 (0.1 miles away)
913-261-2020
Languages Spoken:
English
See accepted insurances

Komal Desai is an Ophthalmologist in Kansas City, Missouri. Dr. Desai is highly rated in 20 conditions, according to our data. Her top areas of expertise are Choroid Plexus Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, Cataract, and Vitrectomy.

Frequently Asked Questions about Dr. Joseph Tauber

How do I make an appointment with Dr. Joseph Tauber?

You can book an appointment with Dr. Joseph Tauber by calling their office at 816-531-9100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph Tauber a top-rated expert for Dry Eye Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph Tauber is classified as an Distinguished expert for Dry Eye Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph Tauber specialize in?

While Dr. Joseph Tauber is a Ophthalmology, they have specific expertise in Dry Eye Syndrome, Meibomianitis, and Conjunctivitis (Pink Eye). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Ophthalmology.

Does Dr. Joseph Tauber participate in research or clinical trials?

Yes. Dr. Joseph Tauber has published 30 articles and abstracts on conditions like Dry Eye Syndrome. You can view a list of Dr. Joseph Tauber's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joseph Tauber accept my insurance?

Dr. Joseph Tauber accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 816-531-9100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tauber's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile